USFDA issues warning letter to Cadila Pharmaceuticals

By PTI
12 November, 2014

The US Food and Drug Administration (USFDA) has issued a warning letter to Ahmedabad-based Cadila Pharmaceuticals for violating current good manufacturing practice norms at its Ankleshwar plant in Gujarat. 

In a warning letter, USFDA said inspectors in March had found significant deviations from standard manufacturing practices at Cadila Pharmaceuticals’ Ankleshwar plant, which manufactures active pharmaceutical ingredients. 

The significant violations included the failure of the company to adequately probe or take corrective action after customer complaints between 2011 and 2012 about unpleasant odours from, and impurities in, certain drug batches sold in the US, the USFDA said. 

The company did not have proper controls in place to prevent the unauthorised manipulation of its electronic raw data, it added. 

“Until all corrections have been completed and FDA has confirmed corrections of the violations and your firm’s compliance with CGMP, FDA may withhold approval of any new applications or supplements listing your firm as an API manufacturer,” USFDA said. 

In addition, the company’s failure to correct these violations may result in FDA refusing admission of articles manufactured at Cadila Pharmaceuticals’ Ankleshwar plant into the US, it added. 

The FDA issued the letter on October 15, and has given the company 15 days to respond. 

The company could not be reached for comments over the FDA letter.


Leave Your Comment
Cadila looks to set up $16M fund to back pharma startups

Cadila looks to set up $16M fund to back pharma startups

Jasleen Kaur Batra 3 years ago
Ahmedabad-based Cadila Pharmaceuticals Ltd is planning to set up a fund with a corpus of Rs 50-100 crore (up to $16 million) to back individuals...
Cadila slapped with US FDA warning on two facilities

Cadila slapped with US FDA warning on two facilities

Joseph Rai 2 years ago
Shares of drugmaker Cadila Healthcare Ltd plunged as much as 15 per cent in intra-day trade on Thursday after the US Food and Drug Administration...
Bain-backed drugmaker Emcure gets US FDA warning

Bain-backed drugmaker Emcure gets US FDA warning

Joseph Rai 1 year ago
The US Food and Drug Administration has sent a warning letter to Emcure Pharmaceuticals for ‘significant violations’ of current good manufacturing practice at its Pune-based...
No Comments

USFDA issues warning letter to Cadila Pharmaceuticals

Powered by WordPress.com VIP